Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,608 shares of the biopharmaceutical company’s stock after selling 3,581 shares during the period. Principal Financial Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,918,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of ALNY. Huntington National Bank grew its position in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals in the third quarter worth $29,000. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at $26,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $42,000. Finally, True Wealth Design LLC lifted its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,122 shares of company stock worth $2,540,455 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALNY. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. TD Cowen upped their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $234.28 on Friday. The stock has a market capitalization of $30.22 billion, a P/E ratio of -89.42 and a beta of 0.32. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The business’s fifty day moving average is $252.99 and its two-hundred day moving average is $257.19. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue was down 33.3% compared to the same quarter last year. During the same period last year, the company posted $1.15 earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.